{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:03:33Z","timestamp":1762297413361},"reference-count":48,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Currently available\n            <jats:italic>Neisseria meningitidis<\/jats:italic>\n            serogroup B (MenB) vaccines are based on outer membrane vesicles (OMVs) that are obtained from wild-type strains. They are purified with the aim of decreasing the lipooligosaccharide (LOS) content and hence reduce the reactogenicity of the vaccine even though LOS is a potential protective antigen. In &lt;2-year-old children, these MenB vaccines confer protection only against strains expressing homologous PorA, a major and variable outer membrane protein. Our objective was to develop a safe LOS-based vaccine against MenB. To this end, we used modified\n            <jats:italic>porA<\/jats:italic>\n            knockout strains expressing genetically detoxified (\n            <jats:italic>msbB<\/jats:italic>\n            gene-deleted) L2 and L3,7 LOSs, allowing the production of LOS-enriched OMVs. The vaccine-induced antibodies were found to be bactericidal against nearly all invasive strains, irrespective of capsular serogroup. In addition, we have also demonstrated that LOS lacking the terminal galactose (with a\n            <jats:italic>lgtB<\/jats:italic>\n            mutation; truncated L3 LOS), but not LOS produced without the\n            <jats:italic>galE<\/jats:italic>\n            gene, induced a bactericidal antibody response in mice similar to that seen for LOS containing the full lacto-\n            <jats:italic>N<\/jats:italic>\n            -neotetraose (L3,7 LOS). In conclusion, a bivalent detoxified LOS OMV-based vaccine demonstrated the potential to afford a broad cross-protection against meningococcal disease.\n          <\/jats:p>","DOI":"10.1128\/iai.01108-08","type":"journal-article","created":{"date-parts":[[2009,3,17]],"date-time":"2009-03-17T00:54:04Z","timestamp":1237251244000},"page":"2084-2093","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":36,"title":["Genetically Modified L3,7 and L2 Lipooligosaccharides from\n            <i>Neisseria meningitidis<\/i>\n            Serogroup B Confer a Broad Cross-Bactericidal Response"],"prefix":"10.1128","volume":"77","author":[{"given":"V.","family":"Weynants","sequence":"first","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Denoe\u0308l","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Devos","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Janssens","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Feron","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Goraj","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Momin","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Monnom","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tans","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vandercammen","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Wauters","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan T.","family":"Poolman","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart B 1330, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.9.6194-6197.2005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200206000-00006"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.036"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00216-9"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00882-06"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.11.4436-4444.1997"},{"key":"e_1_3_2_8_2","unstructured":"European pharmacopeia 2009"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.7.4070-4080.2005"},{"key":"e_1_3_2_10_2","first-page":"81","year":"2001","unstructured":"Frasch, C. E., L. van Alphen, J. Holst, J. T. Poolman, and E. Rosenqvist. 2001. Outer membrane protein vesicle vaccines for meningococcal disease, p. 81-107. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal vaccines: methods and protocols. Humana Press, Totowa, NJ.","journal-title":"Meningococcal vaccines: methods and protocols"},{"key":"e_1_3_2_11_2","first-page":"67","volume":"14","year":"1991","unstructured":"Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Fr\u00f8holm, A. K. Lindbak, B. M\u00f8gster, E. Namork, U. Rye, G. Stabbetorp, R. Winsnes, B. Aase, and O. Closs. 1991. Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14:67-80.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1990.tb00697.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)48372-X"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.1.559-569.2004"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/432102"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/522190"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1995.mmi_18040729.x"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1993.tb01962.x"},{"key":"e_1_3_2_19_2","first-page":"528","volume":"12","year":"1992","unstructured":"Jones, D. H., and S. C. Winistorfer. 1992. Recombinant circle PCR and recombination PCR for site-specific mutagenesis without PCR product purification. BioTechniques12:528-535.","journal-title":"BioTechniques"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0882-4010(92)90022-G"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/589308"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6215(96)00305-9"},{"key":"e_1_3_2_23_2","first-page":"268","year":"2002","unstructured":"Kristiansen, P. A., I. S. Aaberge, K. M\u00f8yner, L. M. N\u00e6ss, K. Bryn, K. Nord, A. G. Skryten, E. Namork, E. Rosenqvist, and K. Harbak. 2002. Tailor-made outer membrane vesicle (OMV) vaccine against the group B meningococcal epidemic in New Zealand\u2014manufacturing and characterisation, p. 268. 13th Int. Pathog. Neisseria Conf., Oslo, Norway, 1 to 6 September 2002.","journal-title":"Tailor-made outer membrane vesicle (OMV) vaccine against the group B meningococcal epidemic in New Zealand\u2014manufacturing and characterisation"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.168.1.107"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6215(02)00395-6"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.12.5290-5295.1994"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.063"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)85220-1"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2000.tb01494.x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/368360"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1982.tb08284.x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(84)90059-3"},{"key":"e_1_3_2_33_2","first-page":"173","year":"2004","unstructured":"Rahman, M. M., M. A. Monteiro, T. Minnini, and V. Pavliak. 2004. Antigenic variation in the inner core region of lipooligosaccharides (LOSs) from Neisseria meningitidis strains representing the L3 immunotype, p. 173. 14th Int. Pathog. Neisseria Conf., Milwaukee, WI, 5 to 10 September 2004.","journal-title":"Antigenic variation in the inner core region of lipooligosaccharides (LOSs) from Neisseria meningitidis strains representing the L3 immunotype"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308364200"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-41-4-236"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1520"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.184.9.2379-2388.2002"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200931200"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.10.5981-5990.2001"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.1.144"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/mr.57.1.34-49.1993"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1995.mmi_18040741.x"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.32.19166"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00411-07"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000258697.05341.2c"},{"key":"e_1_3_2_46_2","first-page":"124","year":"2006","unstructured":"Zollinger, W., E. Moran, D. Schmiel, and B. Brandt. 2006. Specificity of cross-reactive bactericidal antibodies in normal and convalescent human sera (P8.3.19), abstr. no. P8.3.19, p. 124. 15th Int. Pathog. Neisseria Conf., Cairns, Queensland, Australia, 10 to 15 September 2006.","journal-title":"Specificity of cross-reactive bactericidal antibodies in normal and convalescent human sera"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.3.1053-1060.1997"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.09.039"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.03.029"}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.01108-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.01108-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T07:56:28Z","timestamp":1646466988000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.01108-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1128\/IAI.01108-08"],"URL":"https:\/\/doi.org\/10.1128\/iai.01108-08","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"2008-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-03-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}